EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.

Jingyu Wang, Tong Xie, Yuemiao Zhang, Hong Zhang

Cardiorenal Medicine · 2025

DOI: 10.1159/000546238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiorenal Medicine, 2025. Verfasst von Jingyu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Acute Kidney Injury. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recently, a large clinical trial found that treatment with semaglutide significantly reduced the risk of renal damage and cardiovascular death in patients with type 2 diabetes (T2D). To validate these findings and ensure the suitability of the drug, it is necessary to address the renal and cardiac safety of semaglutide in patients with T2D through real-world safety evidence.

Methods

We examined post-marketing data on the use of semaglutide drugs in patients with T2D using disproportionality analysis based on the FDA Adverse Event Reporting System database. We focused on the detection of positive signals for acute and chronic renal injury and cardiac adverse events associated with semaglutide therapy.

Results

A total of 2,380 patients were enrolled in semaglutide therapy in T2D patients with no renal or cardiac positive signals in four algorithmic thresholds, including non-symmetric analysis.

Conclusions

In the current study, we observed no significant cardiac or renal safety signals in patients with T2D treated with semaglutide. Our results provide further support for its use as initial and combination therapy in relevant populations. In addition, these findings highlight the therapeutic potential of semaglutide in patients with chronic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsAcute Kidney InjuryHumansFemaleMaleMiddle AgedAgedProduct Surveillance, PostmarketingUnited StatesAdverse Drug Reaction Reporting SystemsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

Adverse eventCardiac disordersKidney injuryPharmacovigilanceSemaglutideType 2 diabetes

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Renal Division, Peking University First Hospital, Beijing, China.
  • Peking University Institute of Nephrology, Beijing, China.
  • Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
  • Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
  • Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • Renal Division, Peking University First Hospital, Beijing, China, xietong710@163.com.

Zitieren

APA

Wang, J., Xie, T., Zhang, Y., & Zhang, H. (2025). The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS. Cardiorenal Medicine. https://doi.org/10.1159/000546238

Vancouver

Wang J, Xie T, Zhang Y, Zhang H. The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS. Cardiorenal Medicine. 2025. doi:10.1159/000546238

BibTeX
@article{Wang2025,
  author = {Wang, Jingyu and Xie, Tong and Zhang, Yuemiao and Zhang, Hong},
  title = {The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS},
  journal = {Cardiorenal Medicine},
  year = {2025},
  doi = {10.1159/000546238}
}
Kostenlos starten →